Webcast Presentation at H.C. Wainwright Nash Investor Conference (Mar 2018)
DeuteRx to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference Presentation webcast on March 19, 2018
Biochemistry to Bedside Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine (Biochemistry 2018, 57, 472−473)
FASEB Hematological Malignancies 2017 Poster Understanding the Class of Thalidomide Analogs Through the Stabilization & Characterization of Their Interconverting Enantiomers (Jul 2017) - Poster Award
AASLD 2016 Late Breaking Poster Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline-deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH) (Nov 2016)
2015 PNAS Publication Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs (PNAS 2015, 24, 112(12), E1471-1479)
The development of the single, preferred enantiomer from the parent racemic drug, also known as a 'chiral switch', often leads to drugs with superior therapeutic properties. Some successful and profitable ‘chiral switches’ include Prilosec® to Nexium® and Celexa® to Lexapro®.
However, numerous drugs are still developed and marketed as racemic mixtures because their enantiomers chemically interconvert in vivo. To date, DeuteRx has demonstrated the use of deuterium-enabled chiral switching' (DECS) to stabilize and characterize the enantiomers of many racemic active ingredients. This DECS approach to deuterated drugs can provide new composition of matter patent protection and a derisked path to approval.
A 505(b)(2) or similar regulatory path has been successfully implemented for several chiral switches as well as deuterated drugs. Notably, the first deuterated drug approved, Austedo® by Teva / Auspex, was developed as an NCE via a 505(b)(2) pathway.
DeuteRx is a clinical stage biopharmaceutical company dedicated to improving racemic drugs. DRX-065, deuterium-stabilized R-pioglitazone, is in Phase 1 at DeuteRx and is being pursued for NASH and adrenomyeloneuropathy (AMN), a rare monogenic neurological disease. DeuteRx’s second program, DRX-164, is a deuterium-enabled chiral switching' (DECS) of avadomide (CC-122). Avadomide is a racemic cereblon E3 ligase modulator (CELMoD®) currently in development at Celgene for hematological malignancies and solid tumors. DeuteRx published preclinical results demonstrating that the anti-inflammatory and anti-tumorigenic effects of avadomide are due exclusively to the S-enantiomer (Jacques, et al., PNAS 2015, 24, 112(12), E1471-1479).
DeuteRx was founded in 2012 and is the second deuterated drug company founded by the team. The first company, Deuteria Pharmaceuticals Inc., founded in 2010 was acquired by Celgene in 2012.